Navigation Links
Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
Date:2/23/2011

EXTON, Pa., Feb. 23, 2011 /PRNewswire/ -- Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today the commercial launch of ARIDOL® (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades and the company's first product launch in the U.S.  ARIDOL is used to assess bronchial hyperresponsiveness in patients six years of age and older who do not have clinically apparent asthma.  ARIDOL should not be used as a stand alone test to assess asthma or as a screening test for asthma, but as part of a physician's overall assessment of asthma.  ARIDOL can be ordered directly from Pharmaxis and is available to pulmonary function labs and physicians' offices by calling Pharmaxis Customer Service at 1-888-416-1828.  

"ARIDOL is an important advancement in bronchial challenge testing – the first in 20 years – and a significant addition to the tools available to help in an overall assessment of asthma," said Stephen Beckman, President, Pharmaxis, Inc.  "We are excited to provide patients and the medical community with an effective, accurate and reproducible test that can be conducted in the convenience of a pulmonary function lab or physician's office."

ARIDOL is a single-use, indirect test that is easy-to-administer, requires minimal preparation time and a 15% reduction in lung function from baseline for a positive test.  ARIDOL was approved by the U.S. Food and Drug Administration (FDA) on October 5, 2010, and demonstrated safety and efficacy in two Phase III clinical trials.

"The ARIDOL Bronchial Challenge Test takes only about 20 minutes to administer for a positive test and requires a 15% reduction in FEV[1].  Previous options may take up to 40 minutes to implement and require a 20% reduction in FEV[1]," said Bradley Chipps, MD, Capit
'/>"/>

SOURCE Pharmaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
2. Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
3. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
4. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
5. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
6. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
7. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
8. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
9. Pharmaxis Establishes Named Patient Program for Bronchitol
10. Pharmaxis Long-Term Safety Study of Bronchitol Completes
11. Healthpoint Launches New Corporate Identity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Cardinal Health today announced the launch of its new ... increase efficiencies and minimize waste in acute drainage, biopsy ... trays include the essential clinical supplies needed for each ... organizing supplies for procedures and the amount of waste ...
... Pharmaceuticals International, Inc. (NYSE: VRX ... acquired Probiotica Laboratorios Ltda., a leader in sports ... markets a full line of over-the-counter sports nutrition ... percent share of the market. Valeant will acquire ...
Cached Medicine Technology:Cardinal Health Introduces Diagnostic Procedure Trays 2Valeant Pharmaceuticals Acquires Probiotica in Brazil 2
(Date:4/24/2014)... ATLANTA--Dr. Richard Plemper, a professor in the new ... has received a five-year, $2.83 million federal grant ... (RSV) infection. , The grant from the Eunice ... Human Development of the National Institutes of Health ... an anti-RSV drug and at least one distinct ...
(Date:4/24/2014)... better to give than to receive at least if ... suggests. , The study found that 15- and 16-year-olds who ... to family members, are less likely to become depressed than ... keeping the money for themselves. , The researchers detail their ... Sciences . , The study focused on the ventral striatum, ...
(Date:4/24/2014)... In 2009 the influenza pH1N1 virus caused the first ... Finland in May 2009 and killed more than 50 ... infects Finns mainly during flu epidemics (winter/spring seasons). ... to serious complicated illnesses. World Health Organization has recommended ... illness. The disadvantage of this drug is that it ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... Johns Hopkins scientists report that rats exposed to high-energy ... deep space mission, show lapses in attention and slower ... extremely low dose ranges. , The cognitive impairments ... of the animals appear to be linked to ... findings, if found to hold true in humans, suggest ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... how low doses of arsenic, such as the levels found ... affect human physiology. In a paper published online on Dec. ... report that three different steroid hormones all show similar responses ... of arsenic on how these hormones function. ,"Since ...
... by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park ... chronic lymphocytic leukemia (CLL) or diseases that no longer ... the therapy. The results of this study were published ... Clinical Oncology. ,"Chronic lymphocytic leukemia is ...
... arithmetic or to make change for a dollar. She is ... can’t write down her name clearly, nor can she cross ... person. She can sing like a nightingale although her IQ ... she knows hundreds of songs in Italian, German French, Macedonian, ...
... U.S firm Schwarz has found to be potential in reducing ... drugs - the company said on Monday following the results ... the 485-patient study were presented at the North American Regional ... 200-mg dose of the drug, lacosamide, had 14.4 percent fewer ...
... The popular hair-growth drug finasteride, taken by millions of ... antigen (PSA) test,// the standard screening test for prostate ... involving 308 men ranging in age from 40 to ... medical journal The Lancet and is scheduled to be ...
... of obesity, as a causative factor for breast cancer. It ... factor for cancer, heart disease, stroke and diabetes. Scientists have ... breast cancer. ,Latest research has indicated that having ... female hormones, the presence of which elevates the risk of ...
Cached Medicine News:Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 2Health News:Low Doses Of Arsenic Have Broad Impact On Hormone Activity – Says A Researc 3Health News:Heavenly Notes from a Life Etched With Disability: The Strangest Song 2Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
... gel electrophoresis system mirrors a 96-well plate ... of PCR products to take place easily ... (96-well) plate. Loading can be carried out directly ... time in the industry two sets of ...
... Platform is designed with a spring-loaded mechanism ... E-Gel® 48 gel cassettes stay firmly in ... placement and loading from one gel to ... to the robot loading software. In addition, ...
... seamless eliminating the possibility of leakage around glued ... temperature resistant gel trays meaning you do no ... added user friendliness, the Primo tanks come with ... The Primo Gel Systems are designed to be ...
Designed for rapid, routine electrophoresis for nucleic acids. The Mini unit is designed with a choice of two casting systems: standard casting trays that require sealing tape; or aluminum-gated cast...
Medicine Products: